*Press releases are taken from the company websites.
*Titles may be translated independently.
*Please be aware that, since data is collected automatically, there is a possibility of omissions occurring.
*We would like to kindly inform you that we do not collect all press releases from companies.
| Ticker Code | Date | Title | Link |
|---|---|---|---|
| AZN | 8/30/2025 | Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial | http://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-demonstrated-statistically-significant-clinically-meaningful-reduction-sbp-patients-hard-control-hypertension-baxhtn-phase-iii-trial.html |
| MRK | 8/30/2025 | Merck Provides New Results for VERQUVO® (vericiguat) in Patients with Chronic Heart Failure and Reduced Ejection Fraction | https://www.merck.com/news/merck-provides-new-results-for-verquvo-vericiguat-in-patients-with-chronic-heart-failure-and-reduced-ejection-fraction/ |
| NVS | 8/30/2025 | Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain | https://www.novartis.com/news/media-releases/novartis-leqvio-shows-statistically-significant-and-clinically-meaningful-early-ldl-c-goal-achievement-less-muscle-pain |
| TSE:2269 | 8/29/2025 | Notice regarding the acquisition of manufacturing and sales approval for the next-generation mRNA vaccine (replicon) "Costibe® Intramuscular (for 2 people)" for COVID-19 (456KB) | https://www.meiji-seika-pharma.co.jp/pressrelease/2025/detail/pdf/250829_01.pdf |
| TSE:2269 | 8/29/2025 | Published "Integrated Report 2025" | https://www.meiji.com/investor/library/integratedreports/ |
| TSE:4188 | 8/29/2025 | Notice regarding the transfer of representative directors and new management execution system | https://www.mt-pharma.co.jp/news/2025/MTPC250829.html |
| TSE:4506 | 8/29/2025 | Selected as five of the constituent stocks of the ESG investment index adopted by GPIF | https://www.sumitomo-pharma.co.jp/news/20250829.html |
| TSE:4507 | 8/29/2025 | Shionogi Pharmaceutical Co., Ltd. is selected as the Ministry of Economy, Trade and Industry's revised Global South Future-oriented Co-Creation Project Subsidy (Small-scale demonstration/FS project) for the 2024 fiscal year - DX utilization survey project | https://www.shionogi.com/jp/ja/news/2025/08/20250829.html |
| TSE:4530 | 8/29/2025 | Price revision notice | https://www.hisamitsu.co.jp/company/pdf/news_release_250829.pdf |
| TSE:4530 | 8/29/2025 | Notice regarding the resumption of regular shipping of "Aregra®FX" | https://www.hisamitsu.co.jp/whatsnew/pdf/info_250829.pdf |
| TSE:4552 | 8/29/2025 | Medipal and sign a license agreement for the overseas commercialization of JCR GM2G candidates (JR-479) and a joint development and commercialization agreement in Japan | https://ssl4.eir-parts.net/doc/4552/tdnet/2681820/00.pdf |
| TSE:4552 | 8/29/2025 | Integrated Report 2025, March 2025 | https://ssl4.eir-parts.net/doc/4552/ir_material_for_fiscal_ym2/186312/00.pdf |
| TSE:4901 | 8/29/2025 | Fujifilm Holdings, Dentsu, ENEOS, Japan Airlines, McDonald's Japan, and Mitsui Fudosan's Ease of Work NEXT Project to promote women's participation in sales positions | https://holdings.fujifilm.com/ja/news/list/1967 |
| AMGN | 8/29/2025 | AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE | https://www.amgen.com/newsroom/press-releases/2025/08/amgen-to-present-at-the-2025-wells-fargo-healthcare-conference |
| BIIB | 8/29/2025 | FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease | https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-iqliktm-lecanemab-irmb-subcutaneous |